Ma Mei 19, 2022, ua ʻae ka National Medical Products Administration (NMPA) o Kina i ka noi kūʻai aku no Bayer's.Vericiguat(2.5 mg, 5 mg, a me 10 mg) ma lalo o ka inoa inoa Verquvo™.

Hoʻohana ʻia kēia lāʻau lapaʻau i nā poʻe maʻi maʻi me ka hōʻino ʻole o ka naʻau maʻi a me ka haʻihaʻi ejection i hoʻemi ʻia (ejection fraction <45%) i hoʻopaʻa ʻia ma hope o kahi hanana decompensation hou me ka intravenous therapy, e hōʻemi i ka pilikia o ka hale maʻi no ka hōʻole ʻana o ka naʻau a i ʻole ka maʻi diuretic intravenous.

Ua hoʻokumu ʻia ka ʻae ʻana o Vericiguat ma nā hopena maikaʻi mai ka noiʻi ʻo VICTORIA, ka mea i hōʻike ʻia e hiki iā Vericiguat ke hōʻemi hou i ka hopena o ka make ʻana o ka maʻi cardiovascular a me ka hoʻokipa ʻana no ka hōʻemi ʻana o ka naʻau e 4.2% (event absolute risk reduction/100 patient-years) no nā maʻi me ka puʻuwai. ʻaʻole i loaʻa i kahi hanana decompensation hōʻino puʻuwai hou a paʻa i ka lāʻau lapaʻau intravenous me ka haʻihaʻi ejection i hōʻemi ʻia (haʻina ejection <45%).

I Ianuali 2021, ua ʻae ʻia ʻo Vericiguat i ʻAmelika Hui Pū ʻIa no ka mālama ʻana i ka hōʻino ʻole o ka naʻau maʻi maʻi i nā mea maʻi me ka hapa ejection ma lalo o 45% ma hope o ka loaʻa ʻana o kahi hanana hōʻino o ka naʻau.

I ʻAukake 2021, ua ʻae ʻia ka palapala noi lāʻau hou no Vericiguat e ka CDE a hoʻokomo ʻia i loko o ka loiloi mua a me ke kaʻina ʻae ʻia ma ke kumu o "nā lāʻau lapaʻau koʻikoʻi, nā lāʻau hou a hoʻomaikaʻi i nā lāʻau lapaʻau hou no ka pale ʻana a me ka mālama ʻana i nā maʻi maʻi nui. nā maʻi rare”.

I ʻApelila 2022, ka 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure, i hoʻopuka pū ʻia e ka American College of Cardiology (ACC), ka American Heart Association (AHA), a me ka Heart Failure Society of America (HFSA). ), hōʻano hou i ka lāʻau lāʻau lapaʻau o ka puʻuwai puʻuwai me ka hoʻohaʻahaʻa ejection fraction (HFrEF) a hoʻokomo ʻia ʻo Vericiguat i nā lāʻau lapaʻau i hoʻohana ʻia no ka mālama ʻana i nā maʻi me ʻO ka HFrEF kiʻekiʻe a me ka hōʻeha o ka naʻau e pili ana i ka lāʻau maʻamau.

Vericiguathe mea hoʻoulu sGC (soluble guanylate cyclase) me ka mīkini hou i hoʻomohala ʻia e Bayer a me Merck Sharp & Dohme (MSD). Hiki iā ia ke hoʻopili pololei i ka maʻi mīkini hōʻailona cell a hoʻoponopono i ke ala NO-sGC-cGMP.

Ua hōʻike ʻia nā haʻawina preclinical a me nā noiʻi lapaʻau ʻo NO-soluble guanylate cyclase (sGC) -cyclic guanosine monophosphate (cGMP) ala hōʻailona he pahuhopu kūpono no ka piʻi ʻana o ka puʻuwai mau loa a me ka hoʻomaʻamaʻa puʻuwai. Ma lalo o nā kūlana physiological, ʻo kēia ala hōʻailona he ala hoʻoponopono koʻikoʻi no ka mīkini myocardial, ka hana naʻau, a me ka hana endothelial vascular.

Ma lalo o nā kūlana pathophysiological o ka pau ʻole o ka naʻau, hoʻonui ʻia ka mumū a me ka maʻi vascular e hōʻemi i ka NO bioavailability a me ka synthesis cGMP lalo. ʻO ka hemahema cGMP ke alakaʻi nei i ka dysregulation o ka vascular tension, vascular and cardiac sclerosis, fibrosis a me hypertrophy, a me ka coronary a me ka renal microcirculatory dysfunction, no laila ke alakaʻi hou aku nei i ka hōʻeha myocardial holomua, hoʻonui i ka mumū a me ka emi ʻana o ka hana naʻau a me ka renal.